Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Diabetes Mellitus AND Cardiovascular Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44359   clinical trials with a EudraCT protocol, of which   7384   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    344 result(s) found for: Diabetes Mellitus AND Cardiovascular Disease. Displaying page 7 of 18.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2008-005128-10 Sponsor Protocol Number: H9X-MC-GBCK Start Date*: 2009-03-09
    Sponsor Name:Eli Lilly and Company - Indianapolis
    Full Title: Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Patients with Type 2 Diabetes Treated only with Lifestyle Interventions
    Medical condition: Type II Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-003980-21 Sponsor Protocol Number: REX-001-005 Start Date*: 2021-08-31
    Sponsor Name:Rexgenero Limited
    Full Title: The Efficacy and Safety of Intra-Arterial Administration of REX-001 to Treat Ischaemic Ulcers in Subjects with Critical Limb Ischaemia Rutherford Category 5 and Diabetes Mellitus: A Pivotal, Placeb...
    Medical condition: Critical Limb Ischemia in patients with Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10077142 Limb ischemia LLT
    20.0 100000004866 10058069 Critical limb ischemia LLT
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Restarted) AT (Completed) NL (Completed) HU (Prematurely Ended) PL (Prematurely Ended) CZ (Completed) PT (Prematurely Ended) GB (GB - no longer in EU/EEA) LV (Prematurely Ended) LT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003064-21 Sponsor Protocol Number: AAS Start Date*: 2015-01-15
    Sponsor Name:Hospital Universitari de Girona Dr. Josep Trueta
    Full Title: THE USE OF ASPIRIN AS PRIMARY PREVENTION IN PATIENTS WITH DIABETES
    Medical condition: cardiovascular prevention in patients diagnosed in diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10012602 Diabetes mellitus (incl subtypes) HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016178-33 Sponsor Protocol Number: 1245.25 Start Date*: 2010-11-12
    Sponsor Name:Boehringer Ingelheim B.V.
    Full Title: A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in ...
    Medical condition: The study will be performed in patients with type 2 diabetes mellitus and high cardiovascular risk who have insufficient glycaemic control despite diet and exercise and are either treatment naïve o...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) ES (Completed) BE (Completed) FR (Completed) IT (Completed) HU (Completed) PT (Completed) GB (Completed) AT (Completed) GR (Completed) PL (Completed) EE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-000753-24 Sponsor Protocol Number: DC2011LiBrain001 Start Date*: 2011-10-13
    Sponsor Name:VU University Medical Center
    Full Title: Central effects of endogenous GLP-1 and the GLP-1 analog liraglutide on brain satiety and reward circuits and feeding behavior in diabetes.
    Medical condition: diabetes mellitus obesity
    Disease: Version SOC Term Classification Code Term Level
    16.1 10027433 - Metabolism and nutrition disorders 10012594 Diabetes LLT
    16.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003084-19 Sponsor Protocol Number: CLIK066B2204 Start Date*: 2017-05-17
    Sponsor Name:Novartis Pharma AG
    Full Title: A multi-center, randomized, double-blind, parallel-group dose-finding study to assess the effect of 3 doses of LIK066 compared to placebo or empagliflozin in type 2 diabetes mellitus patients with ...
    Medical condition: patients with type 2 diabetes mellitus and heart failure
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10045242 Type II diabetes mellitus LLT
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) GB (Prematurely Ended) DE (Completed) CZ (Prematurely Ended) DK (Prematurely Ended) NO (Completed) NL (Prematurely Ended) HU (Prematurely Ended) ES (Completed) BE (Completed) BG (Prematurely Ended) PL (Prematurely Ended) HR (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001760-19 Sponsor Protocol Number: THR-1442-C-476 Start Date*: 2016-01-07
    Sponsor Name:Theracos Sub, LLC
    Full Title: A double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events
    Medical condition: Type II diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) PL (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-012269-71 Sponsor Protocol Number: BC22140 Start Date*: 2010-03-08
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: Cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2D)
    Medical condition: Type 2 diabetes patients with a recent acute coronary syndrome (ACS) event
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Temporarily Halted) SE (Prematurely Ended) DK (Prematurely Ended) FR (Completed) IE (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000240-34 Sponsor Protocol Number: REX-001-004 Start Date*: 2016-07-07
    Sponsor Name:Rexgenero Limited
    Full Title: The Efficacy and Safety of Intra-Arterial Administration of Rexmyelocel T to treat Critical Limb Ischemia in Subjects with Diabetes Mellitus: A Multicenter, Randomized, Double-Blind, Placebo Contro...
    Medical condition: Critical Limb Ischemia in patients with Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10077142 Limb ischemia LLT
    19.0 100000004866 10058069 Critical limb ischemia LLT
    19.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Restarted) AT (Completed) NL (Ongoing) HU (Completed) PL (Completed) PT (Ongoing)
    Trial results: View results
    EudraCT Number: 2022-003573-32 Sponsor Protocol Number: 2022/ABM/01/00027 Start Date*: 2023-12-28
    Sponsor Name:Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu
    Full Title: A randomized, double-blind, placebo-controlled study to evaluate the effect of allopurinol on the risk of cardiovascular events in patients at high and very high cardiovascular risk, including the ...
    Medical condition: hyperuricemia, hypertension, ischemic stroke, intracerebral haemorrhage, TIA, heart failure, peripheral arterial disease, atrial fibrillation, diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.1 10027433 - Metabolism and nutrition disorders 10020907 Hyperuricemia LLT
    20.0 10047065 - Vascular disorders 10020772 Hypertension PT
    22.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    21.1 10029205 - Nervous system disorders 10044390 Transient ischaemic attack PT
    20.0 10007541 - Cardiac disorders 10019279 Heart failure LLT
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    27.1 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000239-34 Sponsor Protocol Number: PONTIACII Start Date*: 2015-12-30
    Sponsor Name:Medizinische Universität Wien
    Full Title: NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease; a prospective randomized trial
    Medical condition: The purpose of this study is to evaluate the effect of high dose Renin-Angiotensin System (RAS)-antagonists and beta-blocker treatment for the primary prevention of cardiac events in a population o...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) NL (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000950-39 Sponsor Protocol Number: BAY94-8862/17530 Start Date*: 2015-09-09
    Sponsor Name:Bayer AG
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular mor...
    Medical condition: Type II Diabetes Mellitus and Diabetic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) HU (Completed) GB (Completed) AT (Completed) DE (Completed) CZ (Completed) ES (Completed) FI (Completed) PT (Completed) BE (Completed) BG (Completed) NL (Completed) LT (Completed) PL (Completed) FR (Completed) GR (Completed) RO (Completed) IE (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004559-12 Sponsor Protocol Number: SPP635CRD05 Start Date*: 2007-11-07
    Sponsor Name:Speedel Pharma Ltd.
    Full Title: A Phase II a, Double-Blind, Randomized, Parallel-Design, Four-week Study to Investigate the Efficacy and Safety of Two Different Doses of the Renin-inhibitor SPP635 Once Daily in Type II Diabetic P...
    Medical condition: Diabetes mellitus type II with mild to moderate hypertension and albuminuria
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045250 Type II diabetes mellitus with renal manifestations LLT
    9.1 10001580 Albuminuria LLT
    9.1 10045248 Type II diabetes mellitus with other specified manifestations LLT
    9.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-001240-30 Sponsor Protocol Number: CL3-05702-013 Start Date*: 2006-10-31
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Long term double blind comparison of gliclazide MR (30 to 120 mg daily per os) and rosiglitazone (4 to 8 mg daily per os) given in combination with metformin in type 2 diabetic patients.A 2-year in...
    Medical condition: Diabetes mellitus non insulino dependant
    Disease: Version SOC Term Classification Code Term Level
    9.0 10027433 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) LV (Prematurely Ended) DE (Prematurely Ended) LT (Prematurely Ended) CZ (Completed) HU (Completed) SI (Prematurely Ended) AT (Prematurely Ended) GB (Completed) SK (Completed) PT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-004226-28 Sponsor Protocol Number: ATS K016 Start Date*: 2005-01-17
    Sponsor Name:Takeda Pharma GmbH
    Full Title: Effects of Pioglitazone in Patients with Type 2 Diabetes Mellitus and Coronary Heart Disease at High Risk for Cardiovascular Complications
    Medical condition: Type 2 Diabetes mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001885-17 Sponsor Protocol Number: CTSUTHRIVE1 Start Date*: 2006-09-26
    Sponsor Name:University of Oxford
    Full Title: HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): A randomized trial of the long-term clinical effects of raising HDL cholesterol with niacin and MK-0524.
    Medical condition: Cardiovascular disease: History of myocardial infarction; or cerebrovascular atherosclerotic disease (history of presumed ischaemic stroke, transient ischaemic attack or carotid revascularisation);...
    Disease: Version SOC Term Classification Code Term Level
    9.0 10051615 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DK (Completed) SE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002607-17 Sponsor Protocol Number: TSX/01/C Start Date*: 2005-11-18
    Sponsor Name:Prostrakan Pharmaceuticals Ltd
    Full Title: Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus
    Medical condition: Male hypogonadism is generally characterised by abnormally low serum testosterone levels. Symptoms include changes in mood, decreased bone mineral density, increased body fat, decreased muscle mass...
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) ES (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000860-25 Sponsor Protocol Number: CSPP100E2337 Start Date*: 2007-07-27
    Sponsor Name:Novartis Farmacéutica, SA
    Full Title: Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, para determinar si la adición de Aliskiren al tratamiento convencional, en pacientes con diabetes tipo 2 y alto riesg...
    Medical condition: Diabetes tipo 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PT (Prematurely Ended) FR (Completed) FI (Completed) GR (Completed) DE (Completed) DK (Completed) GB (Completed) LT (Completed) BE (Prematurely Ended) HU (Prematurely Ended) NL (Completed) AT (Completed) SE (Prematurely Ended) CZ (Completed) IT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2014-001661-27 Sponsor Protocol Number: ISSBRIL0162 Start Date*: 2014-12-12
    Sponsor Name:Sociedad Española de Cardiología
    Full Title: Comparison of TIcagrelor and clopidogrel in patients with Coronary artery diseaSe and type 2 Diabetes Mellitus (TICS-DM): a randomized pharmacodynamic study
    Medical condition: Coronary artery disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000240-17 Sponsor Protocol Number: ESTIMATE Start Date*: 2017-05-02
    Sponsor Name:Bispebjerg University Hospital
    Full Title: Effect of SGLT2 inhibition on coronary microvascular function in type 2 diabetes
    Medical condition: Coronary microvascular function in patients with type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    19.1 10007541 - Cardiac disorders 10072685 Microvascular coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Sep 24 23:10:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA